# Identification of mechanisms by which cytisine and estrogen inhibit ER stress and exert neuroprotection in Parkinson's disease

> **NIH NIH R01** · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · 2021 · $352,439

## Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, predicted to affect over 12
million people worldwide by 2040. There is no cure for PD and current treatments are merely symptomatic,
which underscores an urgent and unmet need for neuroprotective drugs. One major barrier for the inability to
develop effective and clinically translatable neuroprotective drugs is that no single animal model recapitulates
the complex process that leads to dopaminergic (DA) neuron loss in PD. Therefore, most drugs that succeed in
preclinical animal models fail to work in PD patients. The current proposal addresses this barrier by focusing
on hyperactivated endoplasmic reticulum (ER) stress, which is an established convergent mechanism
downstream of multiple PD-related toxicities. ER stress consists of three signaling arms that culminate in the
translocation of three key proteins – ATF6, XBP1, and CHOP into the nucleus of DA neurons. Moderate
activation of ATF6 and XBP1 is neuroprotective, while chronic, uncontrolled activation of these proteins leads
to DA cell death. By contrast, activation of CHOP invariably causes cell death. Experiments showed that the
nicotinic compound cytisine causes an upregulation of specialized structures called ER exit sites (ERES), and
this is associated with an inhibition of ATF6 and XBP1. Surprisingly, experiments in a 6-hydroxydopamine (6-OHDA)-induced preclinical toxin model of PD showed that cytisine is neuroprotective only in female mice.
Additional preliminary experiments showed that 17-β-estradiol inhibits CHOP expression in DA neurons, which
fits with strong sex-differences observed in the incidence and phenotype of PD, with men being more prone to
developing PD than women. Based on these data, this proposal hypothesizes that cytisine and estrogen exert
neuroprotection in female mice by synergistically inhibiting all three arms (ATF6, XBP1 and CHOP) of
hyperactivated ER stress in DA neurons. Experiments are proposed to determine the extent to which cytisine
requires ERES for exerting neuroprotection by specifically deleting ERES in DA neurons or by using nicotinic
compounds that cannot upregulate ERES. Female mice will be ovariectomized to determine mechanisms by
which specific subtypes of estrogen receptors exert neuroprotection in female mice. On completing
experiments in this proposal, key signaling targets through which cytisine and estrogen mediate
neuroprotective effects will be identified. Success in this proposal will lay groundwork for the long-term goal of
discovering clinically translatable neuroprotective PD drugs that work in both men and women.

## Key facts

- **NIH application ID:** 10101701
- **Project number:** 5R01NS115809-02
- **Recipient organization:** TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
- **Principal Investigator:** Rahul Srinivasan
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $352,439
- **Award type:** 5
- **Project period:** 2020-02-15 → 2025-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10101701

## Citation

> US National Institutes of Health, RePORTER application 10101701, Identification of mechanisms by which cytisine and estrogen inhibit ER stress and exert neuroprotection in Parkinson's disease (5R01NS115809-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10101701. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*